Latest Tumor necrosis factor-alpha Stories
Tokyo, Sept 28, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd.
Tokyo, Sept 26, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd.
Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.
MUMBAI, August 10, 2011 /PRNewswire/ -- - Revamilast is a PDE4 inhibitor, under development for Asthma, Rheumatoid Arthritis and other inflammatory disorders - The molecule successfully completed pre-clinical trials and Phase I studies - Phase I studies on healthy volunteers were carried out mainly in the UK - Glenmark has initiated global Phase IIb studies for both indications in Europe and...
DALLAS, July 29, 2011 /PRNewswire/ -- Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia. "Eleven year-old Bo Anderson was prescribed Humira for a skin condition, psoriasis.
HORSHAM, Pa., July 22, 2011 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONIÂ® (golimumab).
Tokyo, July 1, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd.
In a study that included nearly 14,000 patients with rheumatoid arthritis or psoriasis, the use of certain disease-modifying antirheumatic drugs was found to lower the risk of diabetes.
MEMPHIS, June 13, 2011 /PRNewswire/ -- Humira defect lawyers filed a lawsuit against Abbott Laboratories in federal court today claiming Abbott's blockbuster drug, Humira, caused a fungal infection resulting in the near-death of a Tennessee man.
- A transitional zone between two communities containing the characteristic species of each.